GlassScriptPhysician profile
Timothy S Larson
NPI 1679782676
$4,414.56
in general payments reported to CMS, 2019-2025
15 companies · $2,176 in 2025
The $2,176 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $210 · 2020: $1,100 · 2021: $19.16 · 2022: $209 · 2023: $237 · 2024: $463 · 2025: $2,176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,950 · Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,950.00 |
| Food and Beverage | $926.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $1,950.00 | 2025 | Tevimbra |
| Abbott Laboratories | $1,182.34 | 2020-2022 | |
| Abiomed | $530.13 | 2022-2025 | Impella |
| Boston Scientific Corporation | $224.72 | 2021-2024 | Versacross Access Solution, Lux-Dx Insertable Cardiac Monitor |
| Medtronic, INC. | $91.93 | 2023-2024 | Corevalve Evolut R, Micra |
| Edwards Lifesciences Corporation | $90.01 | 2024 | Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.26 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $76.00 | 2019-2020 | |
| Biotronik INC. | $53.90 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $41.51 | 2019 | |
| Chiesi USA, INC. | $23.97 | 2024 | Cleviprex, Kengreal |
| Novartis Pharmaceuticals Corporation | $19.63 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.32 | 2019 | |
| Heartflow, INC. | $14.96 | 2025 | |
| Amgen INC. | $13.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Larson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.